

Contemporary Management of Patients With Systemic Lupus Erythematosus: A Case-based Approach



Peer-Reviewed Journal Articles, Published Educational Resources, and Consensus Guidelines

Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. *Ann Rheum Dis*. 2020;79:713-723. doi:10.1136/annrheumdis-2020-216924

Fanouriakis A, Tziolos N, Bertias G, Boumpas DT. Update on the diagnosis and management of systemic lupus erythematosus. *Ann Rheum Dis*. 2021;80:14-25. doi:10.1136/annrheumdis-2020-218272

Fernando MMA, Isenberg DA. How to monitor SLE in routine clinical practice. *Ann Rheum Dis*. 2005;64:524-527. doi:10.1136/ard.2003.015248

Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. *N Engl J Med*. 2020;383:1117-1128. doi:10.1056/NEJMoa2001180

Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. *Arthritis Care Res (Hoboken)*. 2012;64(6):797-808. doi:[10.1002/acr.21664](https://doi.org/10.1002/acr.21664)

Lambers WM, Westra J, Jonkman MF, Bootsma H, de Leeuw K. Incomplete systemic lupus erythematosus: What remains after application of American College of Rheumatology and Systemic Lupus International Collaborating Clinics criteria? *Arthritis Care Res (Hoboken)*. 2020;72:607-614. doi:10.1002/acr.23894

Morand EF, Abreu G, Furie RA, Golder V, Tummala R. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus. *Ann Rheum Dis*. 2023;82:639-645. doi:10.1136/ard-2022-222748

Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on lupus nephritis: Core curriculum 2020. *Am J Kidney Dis*. 2020;76:265-281. doi:10.1053/j.ajkd.2019.10.017

Rovin BH, Teng YKO, Ginzler EM, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. *Lancet*. 2021;397:2070-2080. doi:10.1016/s0140-6736(21)00578-x

Tedeschi SK, Johnson SR, Boumpas D, et al. Developing and refining new candidate criteria for systemic lupus erythematosus classification: An international collaboration. *Arthritis Care Res (Hoboken)*. 2018;70(4):571-81. doi:10.1002/acr.23317.

Online Resources

SLEDAI Damage Index Calculator. Available at https://qxmd.com/calculate/calculator_335/sledai-2k

SLICC/ACR Damage Index Calculator. Available at https://qxmd.com/calculate/calculator_336/slicc-acr-damage-index